



HHS Public Access

Author manuscript

Infect Control Hosp Epidemiol. Author manuscript; available in PMC 2015 July 01.

Published in final edited form as:

Infect Control Hosp Epidemiol. 2014 July ; 35(7): 839–844. doi:10.1086/676859.

Outpatient parenteral antimicrobial therapy (OPAT) practices among adult infectious disease physicians

Michael A. Lane¹, Jonas Marschall¹, Susan E. Beekmann², Philip M. Polgreen², Ritu Banerjee³, Adam L. Hersh⁴, and Hilary M. Babcock¹

¹Department of Internal Medicine, Washington University in St. Louis School of Medicine, St. Louis, MO

²Department of Internal Medicine, Carver College of Medicine, University of Iowa, Iowa City, IA

³Department of Pediatric and Adolescent Medicine, Mayo Clinic, Rochester, MN

⁴Pediatric Infectious Diseases, University of Utah, Salt Lake City, UT

Abstract

Objective—To identify current outpatient parenteral antibiotic therapy practice patterns and complications.

Methods—We administered an 11 question survey to adult infectious disease physicians participating in the Emerging Infections Network (EIN), a CDC-sponsored sentinel event surveillance network in North America. The survey was distributed electronically or via facsimile in November and December 2012. Respondent demographic characteristics were obtained from EIN enrollment data.

Results—Overall, 555 (44.6%) of EIN members responded to the survey with 450 (81%) indicating they treated 1 patient with OPAT during an average month. ID consultation was reported to be required for a patient to be discharged on OPAT by 99 (22%) respondents. Inpatient (282/449; 63%) and outpatient (232/449; 52%) ID physicians were frequently identified as being responsible for monitoring lab results. Only 26% (118/448) had dedicated OPAT teams at their clinical site. Few ID physicians have systems to track errors, adverse events or “near-misses” associated with OPAT (97/449; 22%). OPAT complications were perceived to be rare. Among respondents, 80% reported line occlusion/clotting as the most common complication (occurring in 6% of patients), followed by nephrotoxicity and rash (each reported by 61%). Weekly lab monitoring of patients on vancomycin was reported by 77% (343/445) of respondents; whereas 19% (84/445) of respondents reported twice weekly lab monitoring for these patients.

Conclusions—Although utilization of OPAT is common, there is significant variation in practice patterns. More uniform OPAT practices may enhance patient safety.

Corresponding Author & Requests for Reprints: Michael Lane, MD, Washington University School of Medicine, Campus box 8051, 660 S. Euclid Ave, St. Louis, MO 63110, Phone: 314-454-8215, Fax: 314-454-5392, mlane@dom.wustl.edu.

Potential conflicts of interest: All authors report no conflicts of interest relevant to this article.

Keywords

OPAT; medication safety; emerging infections network

Introduction

Over the past 30 years, outpatient parenteral antimicrobial therapy (OPAT) has gained in popularity as a cost-effective strategy for treating a variety of infectious diseases including skin and soft tissue infections^{1, 2}, osteomyelitis^{3, 4}, prosthetic joint infections^{5, 6}, and endocarditis⁷. In a 2006 survey of infectious disease physicians, 94% indicated that patients are commonly set up for OPAT at hospital discharge.⁸ In addition to patients' preference for being treated outside the hospital setting⁹, there are clear cost savings associated with OPAT. Use of OPAT is significantly less expensive than continued inpatient care.¹⁰⁻¹²

In 2004, the Infectious Disease Society of America (IDSA) published practice guidelines suggesting standards for OPAT practices. These guidelines provide recommendations on patient evaluation and selection for OPAT services, antibiotic selection and administration, OPAT team structure, and laboratory monitoring.¹³ A survey of infectious disease (ID) physicians prior to the publication of these guidelines revealed diverse OPAT practices.⁸ Little is known about OPAT practice patterns, complication rates and safety systems since the publication of these guidelines. The aim of this study was to survey adult infectious disease physicians on their current OPAT practices.

Methods

The Emerging Infections Network is a network of ID physicians in North America who provide care to adult and pediatric patients. The network was established in 1995 by the Centers for Disease Control and Prevention (CDC) to establish a provider-based emerging infections sentinel network.¹⁴ The network is also used for surveys of current knowledge and practices of providers. This survey was sent electronically or via facsimile to the 1244 EIN members who provide care to adult patients. The survey was conducted from November to December 2012. After the survey distribution, email reminders were sent to non-respondents 2 and 4 weeks after the initial invitation. The survey consisted of brief introductory text and 11 questions. Survey questions addressed OPAT practice patterns and safety issues. Participants were asked about their participation in OPAT services, and the role of ID consultation prior to discharge or placement of a vascular catheter for designated OPAT recipients. Participants were also asked about who was responsible for monitoring and acting upon laboratory results from patients receiving OPAT. Respondents were queried on their perceptions of the frequency and consequences of OPAT-related complications including lab abnormalities, catheter-associated complications and the development of *Clostridium difficile* or bloodstream infections. One question focused on barriers to providing safe OPAT services to patients. Finally, participants were asked to indicate the frequency of laboratory monitoring during OPAT for several frequently used antibiotics. The survey may be found at <http://ein.idsociety.org/surveys/survey/62/>. Differences in

frequencies were analyzed for statistical significance using χ^2 tests, Student's t-test and Mann-Whitney U-test as appropriate. A P-value of <0.05 was considered significant.

Results

Overall, 555 (44.6%) of 1244 physicians participating in EIN responded to the survey. Respondents came from all US Census regions.¹⁵ Response rates were similar across all Census regions. Respondents were significantly more likely than non-respondents to have 15 years of infectious diseases experience ($p < 0.0001$). EIN members with ≥ 25 years of experience were the largest group of respondents (150/274; 55%), followed by those with 15–24 years of experience (147/292; 50%).

Among respondents, 105 (19%) did not provide care to any patients discharged on OPAT in an average month. Among those that did manage patients on OPAT, monthly patient volume varied widely; 114 respondents (20%) managed 1–5 patients/month, 214 respondents (39%) managed 6–15 patients/month, 80 respondents (14%) managed 16–25 patients/month and 42 (8%) respondents managed >25 patients/month. Respondents ranked the patient's home as the most common location for receiving OPAT followed by infusion centers, dialysis centers and emergency rooms.

Twenty-two percent of respondents reported that ID consultation is required to discharge any patient on IV antibiotics. Of those requiring ID consultation to discharge a patient on OPAT, only 28 (28%) required ID to approve vascular access placement for OPAT. The inpatient (63%) and outpatient (52%) ID physicians were the most commonly identified as being responsible for monitoring and acting upon laboratory results. Ninety-four respondents (21%) indicated the patient's primary care physician was responsible for monitoring laboratory results. Dedicated OPAT teams whose primary job is to monitor patients on OPAT were uncommon with 118 (26%) reporting this service at their primary hospital or clinic. Respondents providing OPAT services to ≥ 16 patients per month were more likely to have a dedicated OPAT team compared to lower volume providers (40% vs 21%, $p < .001$). Lack of a dedicated OPAT team was the single most common barrier reported to providing safe OPAT services (median rank 2), followed by the large number of locations patients receive OPAT, communication issues, and volume of laboratory results (median rank 3).

Only 22% (97) of respondents have a system to track the frequency of errors, adverse events or "near-misses" associated with OPAT. Those providing OPAT services to >16 patients per month were more likely to have error reporting systems than lower volume providers (32% vs 18%, $p = .023$). Line occlusion or clotting, rash and nephrotoxicity were the most commonly reported complications associated with OPAT (Figure 1). Respondents indicated that patients commonly required line exchange or removal or change in antibiotic therapy due to complications from OPAT; hospitalization for OPAT complications was less common (Figure 2). Over the past 5 years, 22% (98) and 48% (214) of respondents reported OPAT-related complications to be less frequent or unchanged, respectively. A minority (67; 15%) reported OPAT-related complications to be more frequent than five years ago.

Although there is some variation, weekly laboratory monitoring was reported to be the most common practice for several common antibiotics (Table 1).

Discussion

We report the results of a survey of a large network of adult infectious diseases physicians regarding their experiences providing OPAT. We found that the utilization of OPAT is common among ID physicians with over 80% of respondents discharging 1 patient on OPAT during an average month. We found significant variability in involvement of ID physicians in selecting patients for OPAT, practice infrastructure and laboratory monitoring practices.

Selecting patients who would benefit from OPAT is critical to treatment success. International OPAT guidelines recommend careful review of patients who might be appropriate for OPAT.^{13, 16} Patients discharged on OPAT must be medically stable to receive continued treatment outside the inpatient hospital setting. In addition, IDSA guidelines recommend an assessment of the patient and caregivers who will be responsible for administering the medications and caring for vascular access devices.¹³ In addition to assessing the patient and caregiver's ability to provide daily OPAT care at home, formal ID consultation facilitates the appropriate selection of antibiotic therapy. Sharma et al. found that requiring ID consultation prior to discharge on OPAT frequently altered the patient's care and resulted in a significant cost savings.¹⁷ At the Cleveland Clinic, ID consultation is required prior to patient discharge on OPAT. In a study of 263 candidates for OPAT, ID consultation resulted in optimization of the antibiotic treatment regimen or significant alterations in the patient's assessment in 84% and 52%, respectively, of patients evaluated by OPAT physicians. Additionally, OPAT was determined to be unnecessary in 27% of patients evaluated, almost half of whom were deemed not to need any antibiotic therapy at all following discharge.¹⁸ Although these studies demonstrate significant benefit to patients, few hospitals require ID consultation prior to discharge. In our study, only 22% of respondents indicated ID consultation was required to initiate OPAT. Our results suggest that there are significant opportunities for improvement in antibiotic stewardship through the use of routine ID consultation prior to OPAT initiation.

Additionally, our survey found that a wide variety of providers are responsible for monitoring and acting upon laboratory results for patients treated with OPAT, including inpatient ID physicians (reported by 63% of respondents), outpatient ID physicians (52% of respondents), patient primary care physicians (21% of respondents), and pharmacists (9% of respondents). While it is possible some variation may be attributable to different models of OPAT delivery,¹⁹ our findings suggest a lack of consensus regarding standard processes to ensure patients receive appropriate monitoring after hospital discharge. Only 26% of respondents indicated that their primary hospital or clinic had a specified provider or team whose primary purpose was to monitor patients receiving OPAT; it is possible that some clinical practices utilize various personnel to perform these duties even though it is not their primary role. Respondents reported many barriers to providing safe OPAT services. The lack of dedicated personnel was the single most common barrier reported by respondents. Although IDSA guidelines recommend a multidisciplinary team to coordinate care and

monitoring laboratory results, our study suggest that these recommendations may be poorly implemented in current practice.

Although prior surveys of infectious disease physicians suggest OPAT complications are common, there is limited data on the frequency of OPAT-related adverse events or hospital readmission.⁸ In a retrospective study of 302 courses of OPAT, significant adverse events were noted in 25%. Renal failure was the most common adverse event, occurring in 7% of OPAT courses.²⁰ Among patients with osteomyelitis treated with OPAT, 5% developed some adverse event.²¹ This OPAT registry also demonstrated that 25.2% of patients treated with vancomycin experienced a vancomycin or IV-line related adverse event.²² Other reports have shown significant rates of decreased renal function, as high as 3.08 patients/1,000 therapy-days among patients treated with select antibiotics.²³ Hospital readmission due to complications of OPAT therapy occurs in 12–16% of patients.^{6, 24} In our study, respondents reported line occlusion or clotting, rash and nephrotoxicity occur commonly, although most believe there has been no change in the frequency of OPAT-related complications over the past 5 years. However, despite the frequency of these complications, fewer than one-quarter have systems to track the frequency of errors, adverse events or “near-misses” associated with OPAT. Given the widespread lack of reporting systems or registries, it is possible that error rates reported by respondents underestimate the true number of patients who experience harm while treated with OPAT.

Although weekly laboratory monitoring was most common for many antibiotics, our results demonstrated some variability in practice. Vancomycin use has become more common as methicillin-resistant *Staphylococcus aureus* rates have increased among hospitalized patients. Vancomycin-associated nephrotoxicity rates have been reported to vary widely from 5–35%.²⁵ Clinical guidelines on vancomycin use suggest once weekly monitoring for hemodynamically stable patients²⁶; however, these guidelines do not address the safety of high vancomycin dose strategies that target a trough concentration of 15–20 mg/L. A subsequent meta-analysis demonstrated an increased risk of nephrotoxicity among patients with vancomycin trough ≥ 15 mg/L compared to those with a trough < 15 mg/L (OR 2.67, 95% CI, 1.95 – 3.65).²⁷ Most respondents in our study report monitoring labs on a weekly basis for patients treated with vancomycin. However, more frequent laboratory monitoring, favored by 19% (86/445) of respondents, may allow for early identification and intervention in patients who develop nephrotoxicity.

This study has several limitations which may limit the generalizability of the results. Although we had >550 respondents, these respondents may not be representative of the entire infectious disease community. Additionally, a significant number of respondents indicated they were not required to be involved in the management of patients discharged on OPAT. Since our survey only targeted EIN members, it is possible that OPAT practices and complication rates identified in our survey are not representative of patients discharged on OPAT by other medical providers. Additionally, recall bias is an inherent limitation of surveys.

Although OPAT has been used for decades to successfully treat a wide array of infectious diseases, our study demonstrates there is tremendous variability in practice patterns among

physicians who provide OPAT services. With increasing focus on improving the quality of medical care and reducing hospital readmissions, standardization of OPAT practices has the potential to provide significant benefit to patients. In order to improve clinical outcomes, robust tracking systems or OPAT registries will need to be developed in order to further develop evidence-based practices and monitor individual patient outcomes.

Acknowledgements

Financial support: Dr. Lane has received career development support from the Goldfarb Patient Safety & Quality Fellowship program and the Barnes-Jewish Hospital Foundation. Dr. Lane was also supported by the Washington University Institute of Clinical and Translational Sciences grants UL1 TR000448 and KL2 TR000450 from the National Center for Advancing Translational Sciences and the KMI Scholars Program grant KM1CA156708 through the National Cancer Institute (NCI) at the NIH. Dr. Lane has also received Loan Repayment support from L30 AR063363. JM was supported by the NIH CTSA (UL1RR024992) and was recipient of a KL2 Career Development Grant (KL2RR024994); he is currently supported by a BIRCWH KL2 career development award (5K12HD001459-13). He is also the section leader for a subproject of the CDC Prevention Epicenters Program Grant CU54 CK 000162; PI Fraser). In addition, JM is funded by the Barnes-Jewish Hospital Patient Safety and Quality Fellowship Program and a research grant by the Barnes-Jewish Hospital Foundation and Washington University's Institute of Clinical and Translational Sciences (ICTS). This publication was supported by Cooperative Agreement Number 1U50CK000187 from the Centers for Disease Control and Prevention. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the Centers for Disease Control and Prevention.

References

1. Leder K, Turnidge JD, Grayson ML. Home-based treatment of cellulitis with twice-daily cefazolin. *The Medical journal of Australia*. 1998; 169(10):519–522. [PubMed: 9861908]
2. Nathwani D. The management of skin and soft tissue infections: outpatient parenteral antibiotic therapy in the United Kingdom. *Chemotherapy*. 2001; 47(Suppl 1):17–23. [PubMed: 11096185]
3. Eron LJ, Goldenberg RI, Poretz DM. Combined ceftriaxone and surgical therapy for osteomyelitis in hospital and outpatient settings. *Am J Surg*. 1984; 148(4A):1–4. [PubMed: 6091473]
4. Tice AD. Outpatient parenteral antimicrobial therapy for osteomyelitis. *Infect Dis Clin North Am*. 1998; 12(4):903–919. [PubMed: 9888029]
5. Esposito S, Noviello S, Leone S, et al. Outpatient parenteral antibiotic therapy (OPAT) in different countries: a comparison. *Int J Antimicrob Agents*. 2004; 24(5):473–478. [PubMed: 15519480]
6. Duggal A, Barsoum W, Schmitt SK. Patients with prosthetic joint infection on IV antibiotics are at high risk for readmission. *Clin Orthop Relat Res*. 2009; 467(7):1727–1731. [PubMed: 19381747]
7. Rehm SJ. Outpatient intravenous antibiotic therapy for endocarditis. *Infect Dis Clin North Am*. 1998; 12(4):879–901. vi. [PubMed: 9888028]
8. Chary A, Tice AD, Martinelli LP, Liedtke LA, Plantenga MS, Strausbaugh LJ. Experience of infectious diseases consultants with outpatient parenteral antimicrobial therapy: results of an emerging infections network survey. *Clinical infectious diseases : an official publication of the Infectious Diseases Society of America*. 2006; 43(10):1290–1295. [PubMed: 17051494]
9. Montalto M. Patients' and carers' satisfaction with hospital-in-the-home care. *International journal for quality in health care : journal of the International Society for Quality in Health Care / ISQua*. 1996; 8(3):243–251.
10. Hinds R, Winkler C, Kane P, Kunkel M. Outpatient Intravenous Antibiotic Therapy in Medicare Patients: Cost-Savings Analysis. *Infectious Diseases in Clinical Practice*. 1995; 4(3):211–217.
11. Poretz DM, Woolard D, Eron LJ, Goldenberg RI, Rising J, Sparks S. Outpatient use of ceftriaxone: a cost-benefit analysis. *The American journal of medicine*. 1984; 77(4C):77–83. [PubMed: 6093525]
12. Williams DN, Bosch D, Boots J, Schneider J. Safety, efficacy, and cost savings in an outpatient intravenous antibiotic program. *Clin Ther*. 1993; 15(1):169–179. discussion 168. [PubMed: 8458046]

13. Tice AD, Rehm SJ, Dalovisio JR, et al. Practice guidelines for outpatient parenteral antimicrobial therapy. IDSA guidelines. *Clinical infectious diseases : an official publication of the Infectious Diseases Society of America*. 2004; 38(12):1651–1672. [PubMed: 15227610]
14. The emerging infections network: a new venture for the Infectious Diseases Society of America. Executive Committee of the Infectious Diseases Society of America Emerging Infections Network. *Clinical infectious diseases : an official publication of the Infectious Diseases Society of America*. 1997; 25(1):34–36. [PubMed: 9243030]
15. [Accessed April 10, 2013] Census Regions and Divisions of the United States. 2013. https://http://www.census.gov/geo/www/us_regdiv.pdf.
16. Chapman AL, Seaton RA, Cooper MA, et al. Good practice recommendations for outpatient parenteral antimicrobial therapy (OPAT) in adults in the UK: a consensus statement. *The Journal of antimicrobial chemotherapy*. 2012; 67(5):1053–1062. [PubMed: 22298347]
17. Sharma R, Loomis W, Brown RB. Impact of mandatory inpatient infectious disease consultation on outpatient parenteral antibiotic therapy. *Am J Med Sci*. 2005; 330(2):60–64. [PubMed: 16103785]
18. Shrestha NK, Bhaskaran A, Scalera NM, Schmitt SK, Rehm SJ, Gordon SM. Contribution of infectious disease consultation toward the care of inpatients being considered for community-based parenteral anti-infective therapy. *Journal of hospital medicine : an official publication of the Society of Hospital Medicine*. 2012; 7(5):365–369. [PubMed: 22315151]
19. Tice AD. Outpatient Parenteral Antibiotic Therapy (OPAT) in the United States: Delivery models and indications for use. *Canadian Journal of Infectious Diseases*. 2000; 11(SUPPL. A):17A–21A.
20. Berman SJ, Johnson EW. Out-patient parenteral antibiotic therapy (OPAT): clinical outcomes and adverse events. *Hawaii medical journal*. 2001; 60(2):31–33. [PubMed: 11258161]
21. Tice A. The use of outpatient parenteral antimicrobial therapy in the management of osteomyelitis: data from the Outpatient Parenteral Antimicrobial Therapy Outcomes Registries. *Chemotherapy*. 2001; 47(Suppl 1):5–16. [PubMed: 11096184]
22. Tice AD, Hoaglund PA, Nolet B, McKinnon PS, Mozaffari E. Cost perspectives for outpatient intravenous antimicrobial therapy. *Pharmacotherapy*. 2002; 22(2 Pt 2):63S–70S. [PubMed: 11837549]
23. Rehm SJ, Longworth DL. Rates of Adverse Events Associated with Community-Based Parenteral Anti-Infective Therapy. *J Clin Outcomes Manage*. 2000; 7(10):23–28.
24. Cervera C, del Rio A, Garcia L, et al. Efficacy and safety of outpatient parenteral antibiotic therapy for infective endocarditis: a ten-year prospective study. *Enfermedades infecciosas y microbiologia clinica*. 2011; 29(8):587–592. [PubMed: 21723004]
25. Elyasi S, Khalili H, Dashti-Khavidaki S, Mohammadpour A. Vancomycin-induced nephrotoxicity: mechanism, incidence, risk factors and special populations. A literature review. *European journal of clinical pharmacology*. 2012
26. Rybak M, Lomaestro B, Rotschafer JC, et al. Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. *Am J Health Syst Pharm*. 2009; 66(1):82–98. [PubMed: 19106348]
27. van Hal SJ, Paterson DL, Lodise TP. Systematic review and meta-analysis of vancomycin-induced nephrotoxicity associated with dosing schedules that maintain troughs between 15 and 20 milligrams per liter. *Antimicrobial agents and chemotherapy*. 2013; 57(2):734–744. [PubMed: 23165462]




Figure 1.
 Number of respondents reporting perceived frequency of specified OPAT Complications
 * DVT – Deep vein thrombosis.




Figure 2. Number of respondents reporting perceived frequency of specified consequences of OPAT Complications

Table 1

Laboratory Monitoring Frequency by Antibiotic

Antibiotic	<1x/Week N (%)	1x/Week N (%)	2x/Week N (%)	3x/Week N (%)	>3x/Week N (%)	Total
Daptomycin	33 (8)	385 (88)	20 (5)	1 (0)	0 (0)	439
Vancomycin	16 (4)	343 (77)	84 (19)	2 (0)	0 (0)	445
Oxacillin/Nafticillin	38 (9)	385 (87)	17 (4)	2 (0)	0 (0)	442
Cephalosporins	44 (10)	384 (87)	11 (2)	1 (0)	1 (0)	441
Carbapenems	44 (10)	388 (87)	12 (3)	0 (0)	0 (0)	444
Amphotericin	22 (5)	98 (24)	194 (47)	91 (22)	10 (2)	415
Aminoglycosides	23 (5)	130 (30)	247 (57)	31 (7)	4 (1)	435